Cited 0 times in
국내 표준 삼제 요법의 제균율에 대한 체계적 문헌 고찰 및 메타분석
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김지현 | - |
dc.contributor.author | 이용찬 | - |
dc.contributor.author | 임현철 | - |
dc.date.accessioned | 2021-12-28T17:14:21Z | - |
dc.date.available | 2021-12-28T17:14:21Z | - |
dc.date.issued | 2021-02 | - |
dc.identifier.issn | 1738-3331 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/187000 | - |
dc.description.abstract | Background/Aims Standard triple therapy, including a proton pump inhibitor, clarithromycin, and amoxicillin, has been recommended as the first-line for Helicobacter pylori infection. However, the eradication rate of standard triple therapy has declined over the past years because of the increasing resistance to clarithromycin in Korea. We analyzed the eradication rates and the 10-year change in the eradication rates in Korea. Methods PubMed, EMBASE, the Cochrane Library, and KoreaMed were searched for studies published between January 2007 and June 2018. The pooled eradication rates and their 95% CIs were estimated using a random-effect logistic regression model. Results Twenty-six randomized controlled studies on standard triple therapy conducted in Korea were selected. The intention-to-treat (ITT) and per protocol analyses showed pooled eradication rates of standard triple therapy of 71.6% (95% CI, 69.9~73.3%) and 79.6% (95% CI, 76.6~82.2%), respectively. The eradication rate decreased with time. The ITT analysis showed that the 14-day therapy (78.1% [95% CI, 75.2~80.7%]) had significantly higher eradication rates than the 7-day therapy (70.0% [95% CI, 68.5~71.4%]) (P<0.01). Conclusions These results suggest that the eradication rate of standard triple therapy, as the first-line therapy, has shown an unacceptable decrease. The eradication rate increased when the duration of therapy was increased to 14 days, but it was not satisfactory. Therefore, other treatment regimens or therapies based on susceptibility tests should be considered for the first-line therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | Korean | - |
dc.publisher | 대한 Helicobacter 및 상부위장관 연구학회 | - |
dc.relation.isPartOf | Korean Journal of Helicobacter and Upper Gastrointestinal Research | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.title | 국내 표준 삼제 요법의 제균율에 대한 체계적 문헌 고찰 및 메타분석 | - |
dc.title.alternative | Eradication Rates of Clarithromycin Triple Therapy in Korea: A Systematic Review and Meta-analysis | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | 강승주 | - |
dc.contributor.googleauthor | 정혜경 | - |
dc.contributor.googleauthor | 이용찬 | - |
dc.contributor.googleauthor | 양효준 | - |
dc.contributor.googleauthor | 박선영 | - |
dc.contributor.googleauthor | 신철민 | - |
dc.contributor.googleauthor | 김성은 | - |
dc.contributor.googleauthor | 임현철 | - |
dc.contributor.googleauthor | 김지현 | - |
dc.contributor.googleauthor | 남수연 | - |
dc.contributor.googleauthor | 신운건 | - |
dc.contributor.googleauthor | 박재명 | - |
dc.contributor.googleauthor | 최일주 | - |
dc.contributor.googleauthor | 김재규 | - |
dc.contributor.googleauthor | 최미영 | - |
dc.identifier.doi | 10.7704/kjhugr.2020.0056 | - |
dc.contributor.localId | A00996 | - |
dc.contributor.localId | A02988 | - |
dc.relation.journalcode | J02030 | - |
dc.subject.keyword | Clarithromycin | - |
dc.subject.keyword | Disease eradication | - |
dc.subject.keyword | Helicobacter pylori | - |
dc.subject.keyword | Meta-analysis | - |
dc.contributor.alternativeName | Kim, Jie-Hyun | - |
dc.contributor.affiliatedAuthor | 김지현 | - |
dc.contributor.affiliatedAuthor | 이용찬 | - |
dc.citation.volume | 21 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 35 | - |
dc.citation.endPage | 47 | - |
dc.identifier.bibliographicCitation | Korean Journal of Helicobacter and Upper Gastrointestinal Research, Vol.21(1) : 35-47, 2021-02 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.